A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer

Study Summary

The main objectives of this study are to determine the feasibility and safety of Belzupacap Sarotalocan (AU-011, bel-sar) treatment of bladder cancer utilizing focal injections with or without laser application.

Conditions

Non-muscle-invasive Bladder Cancer Non-Muscle Invasive Bladder Cancer (&Amp;#34;NMIBC&Amp;#34;) Unresponsive/Intolerant to BCG NMIBC Non-Muscle Invasive Bladder Carcinoma Non-Muscle Invasive Bladder Neoplasms Non-Muscle Invasive Bladder Urothelial Carcinoma Urothelial Carcinoma Bladder

Interventions / Drugs

AU-011 AU-011 in Combination with Medical Laser Adminstration AU-011 in Combination with Medical Laser Administration

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment55 participants

Primary Completion—

Lead SponsorAura Biosciences

Data Retrieved2026-04-11 02:55:09.188968+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.